Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The proliferation and activation of microglial cells is a hallmark of several neurodegenerative conditions. This mechanism is regulated by the activation of the colony-stimulating factor 1 receptor (CSF1R), thus providing a target that may prevent the progression of conditions such as Alzheimer’s disease. However, the study of microglial proliferation in Alzheimer’s disease and validation of the efficacy of CSF1R-inhibiting strategies have not yet been reported. In this study we found increased proliferation of microglial cells in human Alzheimer’s disease, in line with an increased upregulation of the CSF1R-dependent pro-mitogenic cascade, correlating with disease severity. Using a transgenic model of Alzheimer’s-like pathology (APPswe, PSEN1dE9; APP/PS1 mice) we define a CSF1R-dependent progressive increase in microglial proliferation, in the proximity of amyloid-β plaques. Prolonged inhibition of CSF1R in APP/PS1 mice by an orally available tyrosine kinase inhibitor (GW2580) resulted in the blockade of microglial proliferation and the shifting of the microglial inflammatory profile to an anti-inflammatory phenotype. Pharmacological targeting of CSF1R in APP/PS1 mice resulted in an improved performance in memory and behavioural tasks and a prevention of synaptic degeneration, although these changes were not correlated with a change in the number of amyloid-β plaques. Our results provide the first proof of the efficacy of CSF1R inhibition in models of Alzheimer’s disease, and validate the application of a therapeutic strategy aimed at modifying CSF1R activation as a promising approach to tackle microglial activation and the progression of Alzheimer’s disease. Microglial proliferation and activation is a hallmark of Alzheimer’s disease. Olmos-Alonso et al. show that microglial proliferation in Alzheimer’s disease tissue correlates with overactivation of the colony-stimulating factor 1 receptor (CSF1R) pathway. CSF1R blockade arrests microglial proliferation and activation in a mouse model of Alzheimer-like pathology and slows disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The absence of microglia did not significantly alter the levels of Aβ38, Aβ40, or Aβ42, in detergent-soluble or -insoluble cortical and thalamic homogenates in either the 4- or 7- month cohorts (Fig. 5a–h), in line with multiple studies showing that CSF1R inhibition does not affect Aβ production/clearance10,27,28.”
From Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model (2019) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting CSF-1R has recently been reported to ameliorate AD pathology in APP/PS1 mice, where inhibition of CSF-1R reduced microglial proliferation and decreased the inflammatory phenotype of microglia around amyloid plaques [35].”
From Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy (2020) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglial proliferation has been shown to be the main contributor to increased microglial numbers under certain disease states such as ischemia, facial nerve transection, prion disease, and Alzheimer’s disease [42, 61–64].”
From IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the use of these agents is limited in experimental TBI studies, several groups have reported that microglial elimination [via colony-stimulating factor 1 receptor (CSF1R) inhibition] improves behavioral performance and synaptic functioning independent of Aβ accumulation in multiple transgenic mouse models of AD (3xTg, 5xFAD, APP/PS1) (236–238).”
From The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease (2018) · cites this paper as [237]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“activated microglia in AD show increased proliferation (63,64) and increased expression of inflammatory markers such as CD36, CD14, CD11c, MHC-II, and iNOS (65,66)”
From Microglia in Alzheimer's disease (2017) · cites this paper as [64]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 5×
“…pathogenesis is supported by recent genome-wide association studies, highlighting immune-related genes such as CR1 (Jun et al., 2010), TREM2 (Guerreiro et al., 2013; Jonsson et al., 2013) or HLA-DRB5–HLA-DRB1 in association with Alzheimer’s disease (European Alzheimer’s Disease et al.,…”
ResultInfluentialVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 5×
“The contribution of inflammation to disease pathogenesis is supported by recent genome-wide association studies, highlighting immune-related genes such as CR1 (Jun et al., 2010), TREM2 (Guerreiro et al., 2013; Jonsson et al., 2013) or HLA-DRB5–HLA-DRB1 in association with Alzheimer’s disease (European Alzheimer’s Dise…”
InfluentialCSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 2×
“The therapeutic potential of CSF1R inhibitors has been suggested in inflammatory diseases, autoimmune dis- orders, bone disease and cancer (Burns and Wilks, 2011; Pyonteck et al., 2013).”
BackgroundMethodNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 4×
“, 2009), together with tangle pathology (Nelson et al., 2012) or neurodegeneration-related biomarkers (Wirth et al.”
BackgroundInfluentialElmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 1×
“Activated microglia have been demonstrated in transgenic models of Alzheimer’s disease (LaFerla and Oddo, 2005; Jucker, 2010) and have been recently shown to dominate the gene expression landscape of patients with Alzheimer’s disease (Zhang et al., 2013).”
BackgroundMicroglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 2×
“microglia with an activated phenotype (Perry et al., 2010)”
BackgroundSelf-citation
Cited by
Items 201–300 of 533
Neuroinflammation in organophosphate-induced neurotoxicity
Guignet, M. A., & Lein, P. J. (2018) · Advances in neurotoxicology · doi:10.1016/bs.ant.2018.10.003 · Cited by 53
Boström, G., Freyhult, E., Virhammar, J., Alcolea, D. A., Tumani, H., Otto, M., Brundin, R., Kilander, L., Löwenmark, M., Giedraitis, V., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201565 · Cited by 43
Zhang, Q., Yang, C., Liu, T., Liu, L., Li, F., Cai, Y., Lv, K., Li, X., Gao, J., Sun, D., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.021 · Cited by 43
Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 42
Richards, R. I., Robertson, S. A., O'Keefe, L. V., Fornarino, D., Scott, A., Lardelli, M., & Baune, B. T. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00193 · Cited by 36
In Vitro Evaluation of [3H]CPPC as a Tool Radioligand for CSF-1R
Knight, A. C., Varlow, C., Zi, T., Liang, S. H., Josephson, L., Schmidt, K. F., Patel, S., & Vasdev, N. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00802 · Cited by 37
Carrier, M., Šimončičová, E., St-Pierre, M.-K., McKee, C., & Tremblay, M.-È. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.749737 · Cited by 39
The dense-core plaques of Alzheimer’s disease are granulomas
Lemke, G., & Huang, Y. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20212477 · Cited by 37
Nemeth, C. L., Fine, A. S., & Fatemi, A. S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.003 · Cited by 42
Microglial phagocytosis in Alzheimer disease
Brown, G. C., St George-Hyslop, P., Paolicelli, R. C., & Lemke, G. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-025-01162-y · Cited by 36
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
“CSF1R is also a promising target to regulate the inflammatory response of microglia [59].”
BackgroundMethodAn Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis
Uyar, O., Laflamme, N., Piret, J., Venable, M.-C., Carbonneau, J., Zarrouk, K., Rivest, S., & Boivin, G. (2020) · Journal of Virology · doi:10.1128/jvi.01428-20 · Cited by 39
Central Nervous System: (Immunological) Ivory Tower or Not?
Marin, I. A., & Kipnis, J. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.122 · Cited by 39
Farag, A. K., Hassan, A. H. E., Jeong, H., Kwon, Y., Choi, J. G., Oh, M. S., Park, K. D., Kim, Y. K., & Roh, E. J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.057 · Cited by 34
Deng, X., Yang, Q., Wang, Y., Zhou, C., Guo, Y., Hu, Z., Liao, W., Xu, G., & Zeng, R. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106854 · Cited by 39
Guo, S., Cázarez‐Márquez, F., Jiao, H., Foppen, E., Korpel, N. L., Grootemaat, A. E., Liv, N., Gao, Y., van der Wel, N. N., Zhou, B., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c22434 · Cited by 37
Obst, J., Simon, E., Martin-Estebane, M., Pipi, E., Barkwill, L. M., Gonzalez-Rivera, I., Buchanan, F., Prescott, A. R., Faust, D., Fox, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.579000 · Cited by 33
Self-citationPET Evaluation of Microglial Activation in Non-neurodegenerative Brain Diseases
Ghadery, C., Best, L. A., Pavese, N., Tai, Y., & Strafella, A. P. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-0951-x · Cited by 37
Tan, W., Su, P. P., Leff, J., Gao, X., Chen, J., Guan, A. K., Kalyanasundaram, G., Ma, A. I., & Guan, Z. (2022) · Cell Discovery · doi:10.1038/s41421-022-00377-3 · Cited by 39
de Soysa, Y., Therrien, M., Walker, A. C., & Stevens, B. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101651 · Cited by 37
Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology
Alves, S., Churlaud, G., Klatzmann, D., & Cartier, N. (2017) · Brain · doi:10.1093/brain/awx109 · Cited by 33
The diverse roles of macrophages in metabolic inflammation and its resolution
Ray, A. G., Odum, O., Wiseman, D., & Weinstock, A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147434 · Cited by 34
Bhandare, A., Kapoor, K., Powell, K. L., Braine, E. L., Casillas-Espinosa, P. M., O'Brien, T. J., Farnham, M. M. J., & Pilowsky, P. M. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.03.012 · Cited by 34
Gagliardi, F., Narayanan, A., Gallotti, A. L., Pieri, V., Mazzoleni, S., Cominelli, M., Rezzola, S., Corsini, M., Brugnara, G., Altabella, L., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104705 · Cited by 36
Potential for Targeting Myeloid Cells in Controlling CNS Inflammation
Ifergan, I., & Miller, S. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571897 · Cited by 35
Clayton, E. L., Mancuso, R., Nielsen, T. T., Mizielinska, S., Holmes, H., Powell, N., Norona, F., Overgaard Larsen, J., Milioto, C., Wilson, K. M., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx003 · Cited by 32
Self-citationBoakye, P. A., Rančić, V., Whitlock, K., Simmons, D. A., Longo, F. M., Ballanyi, K., & Smith, P. A. (2019) · Journal of Neurophysiology · doi:10.1152/jn.00839.2018 · Cited by 34
Unravelling the glial response in the pathogenesis of Alzheimer's disease
Alibhai, J. D., Diack, A. B., & Manson, J. C. (2018) · The FASEB Journal · doi:10.1096/fj.201801360r · Cited by 31
Blue, E., Bis, J. C., Dorschner, M. O., Tsuang, D. W., Barral, S., Beecham, G. W., Below, J. E., Bush, W. S., Butkiewicz, M., Cruchaga, C., et al. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000485503 · Cited by 32
Entanglement of CCR5 and Alzheimer’s Disease
Li, T., & Zhu, J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00209 · Cited by 36
Microglia-driven inflammation induces progressive tauopathies and synucleinopathies
Lee, S. H., Bae, E.-J., Park, S. J., & Lee, S. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01450-z · Cited by 39
Meng, J., Ni, J., Wu, Z., Jiang, M., Zhu, A., Qing, H., & Nakanishi, H. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1083596 · Cited by 30
Zuroff, L., Torbati, T., Hart, N. J., Fuchs, D., Sheyn, J., Rentsendorj, A., Koronyo, Y., Hayden, E. Y., Teplow, D., Black, K., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01449 · Cited by 32
Zhang, S.-T., Hu, L., Han, C., Huang, R., Ooi, K., Qian, X., Ren, X., Chu, D.-C., Zhang, H.-L., Du, D.-S., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s329230 · Cited by 24
Ye, C., Wang, S., Niu, L., Yang, F., Wang, G., Wang, S., Xie, J., Chen, Y., Qi, J., Shen, H., et al. (2024) · Theranostics · doi:10.7150/thno.98587 · Cited by 35
Alfei, S., & Zuccari, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020844 · Cited by 29
Glial Cell Dynamics in Neuroinflammation: Mechanisms, Interactions, and Therapeutic Implications
García‐Domínguez, M. (2026) · Biomedicines · doi:10.3390/biomedicines14010115 · Cited by 36
Dorababu, A. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103299 · Cited by 28
Hou, B., Jiang, C. S., Wang, D., Wang, G., Wang, Z.-N., Zhu, M., Kang, Y., Su, J., Wei, P., Ren, H., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00267 · Cited by 31
Pons, V., Laflamme, N., Préfontaine, P., & Rivest, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00047 · Cited by 30
“Taking into consideration that CSF1R signaling pathway is known to be essential for microglia proliferation in pathological conditions (14, 15), our data are unexpected.”
BackgroundMetcalfe, S. M., Bickerton, S., & Fahmy, T. M. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161206141744 · Cited by 27
Rose, K. N., Barlock, B. J., DaSilva, N. A., Johnson, S. L., Liu, C., Ma, H., Nelson, R. B., Akhlaghi, F., & Seeram, N. P. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1672009 · Cited by 29
Choi, G. E., Chae, C. W., Park, M. R., Yoon, J. H., Jung, Y. H., Lee, H. J., & Han, H. J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04313-2 · Cited by 32
Obst, J., Mancuso, R., Simon, E., & Gómez‐Nicola, D. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.08.006 · Cited by 28
Self-citationMedawar, E., Benway, T. A., Liu, W., Hanan, T. A., Haslehurst, P., James, O. T., Yap, K., Muessig, L., Moroni, F., Nahaboo Solim, M. A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.006 · Cited by 26
Lin, L., Song, G., Zhang, H., Yin, Y., Xin, S.-M., Ding, L., & Li, Y. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.08.001 · Cited by 26
Microglia across evolution: from conserved origins to functional divergence
Shimizu, T., & Prinz, M. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01368-6 · Cited by 30
Guerrero‐Carrasco, M., Targett, I. L., Olmos‐Alonso, A., Vargas‐Caballero, M., & Gómez‐Nicola, D. (2024) · Glia · doi:10.1002/glia.24532 · Cited by 29
Self-citationNeuroglia as targets for drug delivery systems: A review
Madhusudanan, P., Reade, S., & Shankarappa, S. A. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.08.013 · Cited by 27
Human Glial Cells as Innovative Targets for the Therapy of Central Nervous System Pathologies
Magni, G., Riboldi, B., & Ceruti, S. (2024) · Cells · doi:10.3390/cells13070606 · Cited by 30
Vishnumukkala, T., Nassir, C. M. N. C. M., Hein, Z. M., Gopalakrishna, P. K., Karikalan, B., Alkatiri, A., Jagadeesan, S., Naik, V. R., Thomas, W., Moklas, M. A. M., et al. (2025) · Cells · doi:10.3390/cells14191497 · Cited by 32
Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice
Lam, S., Hérard, A., Boluda, S., Petit, F., Eddarkaoui, S., Cambon, K., The Brainbank Neuro-CEB Neuropathology Network, Letournel, F., Martin‐Négrier, M., Faisant, M., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01410-y · Cited by 31
Martin-Estebane, M., & Gomez-Nicola, D. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00149 · Cited by 25
Tangavelou, K., & Bhaskar, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212335 · Cited by 25
ADeditome provides the genomic landscape of A-to-I RNA editing in Alzheimer’s disease
Wu, S., Yang, M., Kim, P., & Zhou, X. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa384 · Cited by 25
Revuelta, M., Urrutia, J., Villarroel, Á., & Casis, Ó. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.868842 · Cited by 25
Takatori, S., Kondo, M., & Tomita, T. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00383-4 · Cited by 29
Discovery of a CSF-1R inhibitor and PET tracer for imaging of microglia and macrophages in the brain
van der Wildt, B., Klockow, J., Miao, Z., Reyes, S. T., Park, J. H., Shen, B., & Chin, F. T. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.10.003 · Cited by 23
Catale, C., Bisicchia, E., Carola, V., & Viscomi, M. T. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.02.032 · Cited by 24
Commins, S., & Kirby, B. P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104363 · Cited by 25
Yuan, X., Tang, R., Jia, Z., Chen, Y., Liu, J., & Liu, Y. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.142679 · Cited by 22
Bobotis, B. C., Halvorson, T., Carrier, M., & Tremblay, M. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1317125 · Cited by 22
Nakanishi, H., Nonaka, S., & Wu, Z. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200708125130 · Cited by 22
Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer’s Disease
Xie, J., Wang, H., Lin, T., & Bi, B. (2017) · BioMed Research International · doi:10.1155/2017/2986460 · Cited by 22
Tang, M.-Y., Gorin, F. A., & Lein, P. J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.05 · Cited by 25
The Dual Nature of Microglia in Alzheimer’s Disease: A Microglia-Neuron Crosstalk Perspective
Xie, Z., Meng, J., Wu, Z., Nakanishi, H., Hayashi, Y., Kong, W., Lan, F., Narengaowa, Yang, Q., Qing, H., et al. (2023) · The Neuroscientist · doi:10.1177/10738584211070273 · Cited by 19
The Role of Microglial Depletion Approaches in Pathological Condition of CNS
Tahmasebi, F., & Barati, S. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01326-8 · Cited by 22
Li, S., Sun, Y., Gao, Y., Yu, X., Zhao, C., Song, X., Han, F., & Yu, J. H. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115765 · Cited by 21
Positron emission tomography–guided magnetic resonance spectroscopy in Alzheimer disease
Sheikh‐Bahaei, N., Sajjadi, S. A., Manavaki, R., McLean, M. A., O'Brien, J. T., & Gillard, J. H. (2018) · Annals of Neurology · doi:10.1002/ana.25202 · Cited by 20
Hayashi, S., Hoerder‐Suabedissen, A., Kiyokage, E., Maclachlan, C., Toida, K., Knott, G. W., & Molnár, Z. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa379 · Cited by 20
Zhang, Z., Jin, P., Guo, Z., Tu, Z., Yang, H., Hu, M., Li, Q., Liu, X., Li, W., & Hou, S. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03734-9 · Cited by 20
Patir, A., Barrington, J., Szymkowiak, S., Brezzo, G., Straus, D., Alfieri, A., Lefèvre, L., Liu, Z., Ginhoux, F., Henderson, N. C., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114250 · Cited by 20
Zhang, Z., Niu, K., Huang, T., Guo, J., Xarbat, G., Gong, X., Gao, Y., Liu, F., Shan, C., Su, W., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-024-00846-4 · Cited by 29
Multicellular hypothesis for the pathogenesis of Alzheimer's disease
Goetzl, E. J., & Miller, B. L. (2017) · The FASEB Journal · doi:10.1096/fj.201601221r · Cited by 20
Choi, G. E., Park, J. Y., Park, M. R., Yoon, J. H., & Han, H. J. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102821 · Cited by 21
Irons, D. L., Meinhardt, T., Allers, C., Kuroda, M. J., & Kim, W. (2019) · Brain Pathology · doi:10.1111/bpa.12731 · Cited by 20
Bañuelos, M. M., Zavaleta, Y. J. A., Roldan, A., Reyes, R.-J., Guardado, M., Rojas, B. C., Nyein, T., Vega, A. R., Santos, M., Huerta‐Sánchez, E., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121024119 · Cited by 41
Tong, G., Izquierdo, P., & Raashid, R. A. (2017) · The Open Neurology Journal · doi:10.2174/1874205x01711010027 · Cited by 18
Treatment With the CSF1R Antagonist GW2580, Sensitizes Microglia to Reactive Oxygen Species
Soto‐Díaz, K., Vailati-Riboni, M., Louie, A. Y., McKim, D. B., Gaskins, H. R., Johnson, R. W., & Steelman, A. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734349 · Cited by 22
Li, K., Ran, B., Wang, Y., Liu, L., & Li, W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.999061 · Cited by 18
“In APP/PS1 mice, microglia proliferation is associated with CSF1Rdependent promitosis as AD progresses, and targeted regulation of CSF1R has been shown to improve memory (Olmos-Alonso et al., 2016).”
BackgroundOren, R. L., Kim, E. J., Leonard, A. K., ROSNER, B. A., Chibnik, L. B., Das, S., Grodstein, F., Crosby, G. J., & Culley, D. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-34447-7 · Cited by 18
Conedera, F. M., Runnels, J. M., Stein, J. V., Alt, C., Enzmann, V., & Lin, C. P. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02867-x · Cited by 19
Inhibiting CSF1R alleviates cerebrovascular white matter disease and cognitive impairment
Askew, K. E., Beverley, J., Sigfridsson, E., Szymkowiak, S., Emelianova, K., Dando, O., Hardingham, G. E., Duncombe, J., Hennessy, E., Koudelka, J., et al. (2023) · Glia · doi:10.1002/glia.24481 · Cited by 20
Self-citationKraya, T., Quandt, D., Pfirrmann, T., Kindermann, A., Lampe, L., Schroeter, M. L., Kohlhase, J., Stoevesandt, D., Hoffmann, K., & Villavicencio‐Lorini, P. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.595 · Cited by 22
Vicente-Rodríguez, M., Mancuso, R., Peris-Yague, A., Simmons, C., NIMA Consortium, Wlazly, D., Dickinson, A., Foster, A., Knight, C., Leckey, C., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02769-y · Cited by 17
“JNJ527 was incorporated into mouse chow 12 weeks after prion infection as previously described by Olmos-Alonso [35], for a final dose of 30 mg/kg with an average daily ingestion of 5 g of food per mouse for 4 weeks.”
MethodSelf-citationNiche-specific therapeutic targeting of myeloid cells in the central nervous system
Frosch, M., & Prinz, M. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.016 · Cited by 20
Ardıç, N., & Dinç, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1752471 · Cited by 21
Leinenga, G., Bodea, L., Schröder, J., Sun, G., Zhou, Y., Song, J. H., Grubman, A., Polo, J. M., & Götz, J. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10329 · Cited by 19
The role of microglia in the pathogenesis of diabetic-associated cognitive dysfunction
Xu, W., Wang, X., Hou, X., Yang, Y., Ma, R., Lv, R., & Yin, Q. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1246979 · Cited by 19
Meng, J., Pan, P., Guo, G., Chen, A., Meng, X., & Liu, H. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03259-5 · Cited by 17
Kodali, M., Madhu, L. N., Somayaji, Y., Attaluri, S., Huard, C., Panda, P. K., Shankar, G., Rao, S., Shuai, B., Gonzalez, J. J., et al. (2024) · Aging Cell · doi:10.1111/acel.14398 · Cited by 21
Pathogenesis and therapeutic applications of microglia receptors in Alzheimer’s disease
Fu, J., Wang, R., He, J., Liu, X., Wang, X., Yao, J., Liu, Y., Ran, C., Ye, Q., & He, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1508023 · Cited by 25
Aarhus, T. I., Bjørnstad, F., Wolowczyk, C., Larsen, K. U., Rognstad, L., Leithaug, T., Unger, A., Habenberger, P., Wolf, A., Bjørkøy, G., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00428 · Cited by 16
Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease
Alshamrani, M. (2023) · Antibodies · doi:10.3390/antib12020041 · Cited by 22
Green, J. R., Mahalingaiah, P. K. S., Gopalakrishnan, S. M., Liguori, M. J., Mittelstadt, S. W., Blomme, E. A. G., & Vleet, T. R. V. (2023) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2023.107468 · Cited by 23
Li, H., Guan, M., Zhang, N.-N., Wang, Y., Liang, T., Wu, H., Wang, C., Sun, T., & Liu, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117011 · Cited by 17
Three-way interaction model to trace the mechanisms involved in Alzheimer’s disease transgenic mice
Khayer, N., Marashi, S., Mirzaie, M., & Goshadrou, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184697 · Cited by 16
Gene expression profiles in brain of male juvenile zebrafish (Danio rerio) treated with triclosan
Wang, F., Wang, R., Liu, F., & Wan-guang, C. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.10.014 · Cited by 16
Grigoletti-Lima, G. B., Lopes, M. G., Franco, A. T. B., Damico, A. M., Boer, P. A., & Gontijo, J. A. R. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210297 · Cited by 16
Daura, E., Tegelberg, S., Hakala, P., Lehesjoki, A., & Joensuu, T. H. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1069122 · Cited by 16
Metadata
- Authors
- Olmos-Alonso, A., Schetters, S. T. T., Sri, S., Askew, K., Mancuso, R., Vargas-Caballero, M., Holscher, C., Perry, V. H., & Gomez-Nicola, D.
- Affiliations
- University of Southampton (GB)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-08
- Volume
- 139
- Issue
- 3
- Pages
- 891-907
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC4766375
- OpenAlex
- W2222356562
- Cited by
- 532
- References
- 66
- Citations by year
- 2026: 38 · 2025: 50 · 2024: 50 · 2023: 57 · 2022: 45 · 2021: 79 · 2020: 51 · 2019: 44 · 2018: 51 · 2017: 37 · 2016: 30
- FWCI
- 29.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Brain (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Alzheimer's Society
- Medical Research Council (MR/K022687/1)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- CSF1R inhibition, microglial proliferation, Alzheimer's disease, GW2580, tyrosine kinase inhibitors, APP/PS1 mice, amyloid plaques, microglial activation, anti-inflammatory phenotype, synaptic degeneration, memory impairment, neuroinflammation, disease progression
- MeSH terms
- Alzheimer Disease, Animals, Anisoles, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Pyrimidines, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor, Drug Delivery Systems, Microglia, Disease Progression, Protein Kinase Inhibitors, Cell Proliferation, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.